(PharmaNewsWire.Com, February 27, 2017 ) Publisher's clinical trial report, "Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016" provides an overview of Myelodysplastic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Publisher Clinical Trial Reports are generated using Publisher's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Five Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 15 Clinical Trials by Phase in G7 Countries 16 Clinical Trials in G7 Countries by Trial Status 17 Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 18 Clinical Trials by Phase in E7 Countries 19 Clinical Trials in E7 Countries by Trial Status 20 Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Subjects Recruited Over a Period of Time 25 Clinical Trials by Sponsor Type 26 Prominent Sponsors 27 Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials 28 Prominent Drugs 30 Latest Clinical Trials News on Myelodysplastic Syndrome 31 Mar 24, 2016: Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes Published in Oncotarget 31 Mar 21, 2016: Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes 31 Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on SY-1425 in Blood Cancers at Upcoming AACR Annual Meeting 32 Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting 32 Mar 09, 2016: Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology 33 Feb 15, 2016: Phase 3 Study Demonstrates Aranesp (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome 33 Feb 03, 2016: Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47 34 Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies 34 Jan 11, 2016: Celator Pharmaceuticals Announces Participation in Cardiff University Clinical Trial in Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (AML19) 35 Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 36 Clinical Trial Profile Snapshots 37
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
